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A B S T R A C T
Showing modest eﬃcacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector
and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of
a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like
particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41
presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-
fusion conformation. We tested diﬀerent prime/boost combinations of these components in mice and showed
that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have
the most robust Gag-speciﬁc CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to
stimulation with ﬁve Gag epitopes. The same immunization group elicited the best systemic and mucosal
antibody responses to Gag and dgp41 with a bias towards IgG1.
1. Introduction
Despite the success of antiretroviral treatment, human immunode-
ﬁciency virus (HIV) still causes millions of new infections every year,
primarily in regions of the world with limited access to healthcare,
making the need for a vaccine more apparent every year. To date, even
the most successful HIV-1 vaccine clinical trial, the Phase III Thai Trial
(RV144) had only modest and short-lived eﬃcacy, thus leaving room
for improvement (Rerks-Ngarm et al., 2009). The Thai Trial used a
non-replicating canarypox viral vector (ALVAC) carrying recombinant
genes for Gag, Pol and the surface subunit of the envelope (ENV)
protein (gp120) followed by an AIDSVAX protein boost consisting of
recombinant gp120 B/E produced in Chinese hamster ovary (CHO)
cells. While ALVAC and AIDSVAX showed no protection when tested
individually, their combination in RV144 was modestly protective and
provided some valuable information on immune correlates of protec-
tion. The most direct immune correlates of protection pertained to
(antibody) Ab responses against the V1-V2 loop of gp120 and revealed
the importance of polyfunctional, non-neutralizing Abs (Haynes et al.,
2012; Yates et al., 2014; Chung et al., 2014; Liao et al., 2013). This
short-lived humoral response faded over time and did not provide
long-lasting protective advantage over the placebo arm (Yates et al.,
2014). The results of the RV144 trial indicated the strength of a prime-
boost approach integrating on a live vector with a subunit protein
vaccine. However, the modest eﬃcacy of the trial also suggests that the
particular combination of the speciﬁc antigens chosen can be further
optimized (Haynes et al., 2012; Yates et al., 2014; Corey et al., 2015;
McMichael and Koﬀ, 2014; Prentice et al., 2015).
Because of its surface exposure, its immunogenicity, and the critical
roles it plays during target-cell infection, gp120 has been a natural
target for vaccine development since the early days of HIV-1 research
(Burton and Mascola, 2015; Mascola and Haynes, 2013). This, how-
ever, has proven to be far from straightforward, because gp120 also
functions as a highly mutable decoy with most of its functionally
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important immunogenic sites conformationally occluded or shielded by
glycans. In fact, monomeric preparations of gp120, as well as various
preparations aimed at presentation of gp120 trimers, have repeatedly
failed to induce protective immune responses in animal models or
humans, with the sole and modest exception of the Thai Trial (McGuire
et al., 2014; Jacob et al., 2015; Moore et al., 2015; Haynes et al., 2016).
In contrast, far fewer studies have examined gp41. It contains
highly immunogenic determinants that induce production of Abs that
are among the ﬁrst to arise during acute HIV-1 infection but are of very
limited protective value, showing little or no antiviral activities (Burton
and Mascola, 2015; Liao et al., 2011; Bonsignori et al., 2012). These
immunodominant epitopes are located in a region of the protein
spanning the two heptad repeat domains and in particular within the
loop that connects them (Zolla-Pazner, 2004) and are exposed on the
gp41 “stump” in its six-helical bundle conformation upon removal of
the gp120 subunit (Burton and Mascola, 2015). Still, gp41 was found to
be the target of a number of broadly neutralizing Abs (bnAbs) directed
against conformational (35O22 binding at the gp41-gp120 interface)
(Huang et al., 2014) and linear epitopes (2F5, 4E10, Z13 and 10E8 that
recognize closely situated sites within the membrane proximal external
region, MPER) (Parker et al., 2001; Cardoso et al., 2005; Nelson et al.,
2007; Huang et al., 2012).
Beyond neutralization, anti-MPER Abs, including the above-men-
tioned bnAbs, were found to exhibit other potent anti-HIV-1 activities
including transcytosis blockade (Tudor et al., 2012; Shen et al., 2010;
Matoba et al., 2004, 2008, 2009), Ab-dependent cell-mediated cyto-
toxicity (ADCC) (Tudor and Bomsel, 2011; Hessell et al., 2007) and
curbing of dendritic cell-mediated trans-infection (Tudor et al., 2012;
Sagar et al., 2012; Magerus-Chatinet et al., 2007). Moreover, passive
immunization with these bnAbs provided impressive protection against
mucosal transmission of a simian-HIV hybrid (SHIV) in the macaque
model (Baba et al., 2000; Hessell et al., 2010; Klein et al., 2013a). Anti-
MPER Abs with anti-viral activities were also described in mucosal
secretions of highly-exposed but seronegative individuals (Kaul et al.,
1999, 2001; Pastori et al., 2000; Devito et al., 2000a, 2000b; Tudor
et al., 2009). Lastly, anti-MPER Abs that were passively passed through
breast milk from infected mothers to their uninfected babies were
correlated with protection (Diomede et al., 2012; Pollara et al., 2015).
Despite their long-standing promise, anti-MPER bnAbs are natu-
rally rare and are notoriously diﬃcult to elicit. For example, less than
25% of HIV-1-infected patients develop broad and potent nAbs, which
even if present require ~2–4 years to produce (Burton and Mascola,
2015; Mascola and Haynes, 2013; Haynes et al., 2016; Mascola and
Monteﬁori, 2010). Several explanations have been suggested, including
a lengthy maturation process involving many somatic mutations and
extensive aﬃnity maturation (Klein et al., 2013b; Kepler et al., 2014),
and clonal deletion of the B-cell lines secreting such bnAbs that were
shown to be partially autoreactive (Verkoczy et al., 2010, 2011, 2013).
Interestingly, many of the autoreactivity targets are lipids that can be
found in both the plasma membrane of the host cell and in the viral
envelope (Haynes et al., 2005; Alam et al., 2007, 2009; Irimia et al.,
2016).
It is widely accepted that the membrane milieu of the MPER region
plays a major role in the functional immunogenicity of gp41 (Alam
et al., 2009; Chen et al., 2014). Both the metastable native conforma-
tion of the gp120-gp41 trimer and the highly stable post-fusion
conformations do not expose the neutralizing epitopes (Frey et al.,
2008, 2010; Buzon et al., 2010; Pancera et al., 2014), and fail to
eﬃciently elicit bnAbs (Williams et al., 2015; Sanders et al., 2015;
Crooks et al., 2015; Davis et al., 2009; Decker et al., 2005; Labrijn
et al., 2003) or engage the germline B cell precursors for speciﬁc bnAbs
(McGuire et al., 2014; Hoot et al., 2013; Jardine et al., 2013).
An eﬀective MPER-based antigen therefore requires presentation of
the MPER within a context of a membrane and exposure of the region
in a conformation mimicking the putative pre-fusion intermediate. For
example, Bomsel and co-workers used a gp41 peptide (residues 649–
684) spanning the MPER and part of the C-terminal heptad repeat to
decorate liposomes (“virosome”) and demonstrated the ability of the
immunogen to elicit systemic and mucosal antibodies with transcyto-
sis-blocking activity in humans (Leroux-Roels et al., 2013) and nonhu-
man primates that were thereafter protected against a mucosal SHIV
challenge (Bomsel et al., 2011). Together, these results indicate a
strong potential for this antigenic region to be used as a vaccine
component when presented correctly on a membrane.
Our laboratory developed an eﬃcient production method for
enveloped VLPs in the tobacco-relative Nicotiana benthamiana, con-
sisting of Gag and deconstructed-gp41 (dgp41: MPER, transmembrane
domain, and full-length cytoplasmic tail) (Kessans et al., 2013). Such
VLPs display the MPER of gp41 without steric hindrance from gp120,
without the immunodominant epitopes on both Env subunits, and with
a higher antigen load per VLP than what exists in an HIV virion
(Kessans et al., 2016). A similar construct has been shown by us to be a
likely trimer with its bnAb epitopes exposed (Gong et al., 2015). When
administered to mice, these VLPs elicit both serum IgG and mucosal
IgA to Gag and dgp41 antigens (Kessans et al., 2016).
Live viral vectors are appealing as vaccine vehicles for the expres-
sion of HIV-1 antigens due to their proﬁciency for eliciting T cell
responses. For example, a cytomegalovirus (CMV) vector was recently
shown in nonhuman primates to clear an established SIV infection with
dependency on CD8 T cells recognizing non-canonical epitopes on
major histocompatibility complex (MHC) II instead of MHC I (Hansen
et al., 2013a, 2013b). Poxviruses also stand out amongst other viral
vectors [see reviews (Gomez et al., 2012a; Pantaleo et al., 2010; Jacobs
et al., 2009)] as attested by the Thai Trial that employed a canarypox-
based vector and was the ﬁrst and only HIV-1 vaccine clinical trial to
show eﬃcacy (Rerks-Ngarm et al., 2009; Haynes et al., 2012). The
canarypox-based viral vector used in the trial, ALVAC, is not capable of
replication in mammalian cells (Taylor and Paoletti, 1988; Taylor et al.,
1988). Inability to replicate in vivo in humans makes the virus safer to
use as a vaccine or a vaccine vector. However, we hypothesized that
replication could enhance immunogenicity by increasing antigen load
as the virus replicates in vivo.
To test this hypothesis, we turned to a replicating vaccinia virus
strain, NYVAC-KC. The virus was developed from the NYVAC strain
previously rendered replication incompetent in human cells by deletion
of 18 open reading frames from the genome of Copenhagen (Cop), its
parental strain (Tartaglia et al., 1992a). NYVAC-KC contains a re-
insertion of two host-range genes, K1L and C7L, which allows the virus
to replicate in human tissue, thus improving immunogenicity while
remaining highly attenuated (Kibler et al., 2011; Quakkelaar et al.,
2011).
In this study, we describe the development of replicating vaccinia
virus vectors based on NYVAC-KC that express Gag and dgp41 of HIV-
1 as matching antigens to the plant-produced VLPs for prime/boosting
purposes. We show that the viral vectors produce VLPs in vitro and test
the viral vectors in diﬀerent combinations with plant-produced VLPs in
mice. The animal study revealed that these two vaccine components
work in concert to elicit Gag-speciﬁc CD8 T cell responses and both
systemic and mucosal antibodies to Gag and dgp41 peptides in the
immunization group which most closely mimics the Thai Trial.
2. Materials and methods
2.1. Cloning pGNR plasmids for virus recombination
Construction of synthetic genes encoding Gag (from subtype C R5
HIV-1 isolate 1084i, GenBank #AY805330; synthetic construct
GenBank #JX534517) and dgp41 (MPER derived from the B-clade
MN isolate, GenBank #AF075722, transmembrane and C-terminal
domains from the 1084i isolate #AY805330; synthetic construct #
JX534518) was previously described (Kessans et al., 2013). The genes
were cloned into the pGNR plasmid, which harbors a neoGFP selection
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cassette (neomycin resistance gene fused to GFP, known as pGNR)
between homologous recombination arms for the vaccinia TK locus.
Gag and dgp41 genes were ampliﬁed from pTM 488 (Gag) and pTM
602 (dgp41) [described in (Kessans et al., 2013)] into TOPO pCR-2.1
vectors (Invitrogen). Cloning was achieved using AccuStart Taq DNA
polymerase HiFi PCR kit (Quanta Biosciences) with primers oTM 664
(5′-ACTAGTATGGGAGCTAGAGCCTCT-3′′) and 665 1 (5’-CCCGGGT
TATTGAGAGGAAG-3′) for Gag and oTM 666 (5′-ACTAGTATGGG
ATCTCAAACTCAACAA-3′) and 1667 (5′-CCCGGGTTATTGCAAAGCA
G-3′) for dgp41 for the addition of 5′ ﬂanking SpeI and 3′ ﬂanking
XmaI sites, denoted in italics. Ligation reactions were electroporated
into DH5α Escherichia coli and plated onto LB +ampicillin plates.
Gene insertion was conﬁrmed by colony PCR using GoTaq Green
Master Mix (Promega). Plasmids were extracted using the E.Z.N.A.
mini-prep kit (Omega) and sequences veriﬁed using backbone-speciﬁc
primers M13-forward and M13-reverse. The TOPO plasmids were
designated pTM 813 (Gag) and pTM 814 (dgp41). Both pTM 813, 814,
and pGNR were digested with SpeI and XmaI (NEB) and fragments
separated via gel electrophoresis and extracted using QIAquick Gel
Extraction Kit (Qiagen), then ligated into the pGNR backbone using T4
DNA ligase (Promega). Ampicillin resistant DH5α E. coli colonies were
screened by colony PCR and plasmids extracted as above. Sequences
were conﬁrmed with pGNR backbone-speciﬁc primers oTM 686 (5′-
CCCACCCGCTTTTTATAGTAA-3′) and 687 (5′-CGGTTTATCTAACGA
CACAACA-3′). Sequence-veriﬁed pGNR plasmids were named pTM
815 (Gag) and pTM 816 (dgp41).
2.2. Cell lines and viruses
Monkey kidney BSC-40 cells were grown in DMEM (Corning
Cellgro) with 5% FBS plus gentamycin and 2 mM L-glutamine. Baby
hamster kidney BHK cells were grown in MEM (Corning Cellgro) with
5% FBS plus gentamycin. Generation of the parental vaccinia virus
(VACV) strain NYVAC-KC was described previously (Kibler et al.,
2011).
2.3. In vivo recombination (IVR)
Simultaneous transfection/infection [in vivo recombination, IVR
(Kibler et al., 1997; Brandt and Jacobs, 2001)] was performed with
pTM 815 (Gag) and pTM 816 (dgp41) and NYVAC-KC to insert Gag
and dgp41 into the vaccinia virus TK locus. 500 ng of plasmid DNA was
transfected using Lipofectamine and Plus™ Reagent (Invitrogen) per
manufacturer's protocol. This was immediately followed by infection
with NYVAC-KC at an MOI=0.01 in 35 mm2 dishes of BSC-40 cells.
Recombination was allowed to proceed for 24 h followed by addition of
G418 antibiotic (500 μg/mL). Cells were harvested and lysed at 48 h
post infection (hpi). The IVR was used to infect 100 mm2 dishes of
BSC-40 cells for selection of individual antibiotic-resistant plaques for
subsequent expression screening (note: a mutation in the GFP gene
prevented use of ﬂuorescent screening). This process was repeated for
multiple rounds of antibiotic selection before a > 98% pure virus was
isolated as measured by immunoplaque assay.
2.4. Expression screening
Individual antibiotic-resistant plaques were grown in 60 mm2
dishes of BSC-40 cells to CPE and harvested in 1× SDS sample buﬀer
[50 mM Tris-Cl pH 6.8, 2% SDS, 0.1% bromophenol blue, 10%
glycerol, 100 mM β-mercaptoethanol, 1× protease inhibitor cocktail
III (Research Products International Corp., Prospect, IL)] and then
centrifuged through a QiaShredder (Qiagen) for NYVAC-KC-Gag
plaques. For NYVAC-KC-dgp41, cells were lysed with RIPA lysis buﬀer
[1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 1× protease inhibitor
cocktail III, in 1× PBS without calcium or magnesium (Corning)]. RIPA
lysates were mixed with an equal volume of 2× SDS sample buﬀer. Cell
lysates were screened using SDS-PAGE as previously described
(Kessans et al., 2013). Brieﬂy, boiled samples were run on 12%
polyacrylamide gels under denaturing conditions, transferred to nitro-
cellulose membranes (Bio-Rad) and probed with either Gag or dgp41
antibodies and anti-rabbit or anti-human IgG-HRP, respectively.
Proteins were detected via chemiluminescence (ImmunoCruz
Luminol Reagent, Santa Cruz).
2.5. Immunoplaque assays
Immunoplaque assays were performed in 6-well dishes by infecting
BSC-40s with 50 pfu from cell lysates of individual plaques. Once
plaques were visible, the cells were ﬁxed with 1:1 acetone:methanol for
30 min at −20 °C, washed with PBS, then incubated with anti-p24 Gag
polyclonal rabbit serum or 2F5 (obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH: from Dr. Hermann
Katinger) at 1:1000 in 3% FBS-PBS. Secondary biotinylated antibodies
for anti-rabbit IgG or anti-human IgG from Vectastain ABC Kits
(Vector Laboratories, Inc.) were used for detection with DAB perox-
idase substrate (Vector Laboratories, Inc.) per manufacturer's protocol.
After counting positive plaques, cells were stained with Coomassie blue
dye to count the number of negative plaques. Percentages were
calculated by dividing positive plaques by total plaques per well. The
plaque with the highest percentage of positives was used for further
puriﬁcation until a plaque with > 98% purity was identiﬁed and used to
grow stocks.
2.6. Virus stocks
The ﬁnal NYVAC-KC-Gag and NYVAC-KC-dgp41 plaques with >
98% purity determined by immunoplaque assay were grown to CPE in
BHK cells in a 60 mm2 dish for the ﬁrst passage (P1) stock. The P1
stock was titered in BSC-40s and used to infect ﬁve T150 ﬂasks of BHK
cells at an MOI=0.01 for the P2 stock. Cells were harvested at CPE,
subjected to freeze-thaw and sonication, then cell lysates were placed
on a 36% sucrose pad and centrifuged at 22,000 rpm for 80 min at 4 °C
with an SW28 rotor to pellet virions. Partially puriﬁed virions were
resuspended in 10 mM Tris-HCl pH 9.0, their titer determined in BSC-
40s, and were stored in aliquots at −80 °C until further use.
2.7. Vaccinia in vitro VLP production
BSC-40 cells seeded in 100 mm2 dishes were infected with each of
the vectors at an MOI=5 for a total MOI=10. At 24 hpi, medium and
cells were harvested by centrifugation (700×g for 5 min). VLPs in the
clariﬁed medium were subjected to 40% ammonium sulfate precipita-
tion and resuspended in 1× PBS (140 mM NaCl, 2 mM KCl, 10 mM
Na2HPO4, 1 mM KH2PO4, pH 7.4). Aliquots were boiled and analyzed
by SDS-PAGE for presence of Gag and dgp41 as described above.
2.8. Expression in plants of VLPs and their puriﬁcation
HIV-1 Gag/dgp41 VLPs were expressed and puriﬁed as previously
described (Kessans et al., 2013). Brieﬂy, Gag transgenic N. benthami-
ana plants were inﬁltrated with Agrobacterium tumefaciens harboring
pTM 602 with the dgp41 gene and leaf tissue was harvested 4–6 days
post inﬁltration (dpi). Leaf tissue was crushed in a blender in extraction
buﬀer (25 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM
sodium ascorbate, 1 mM PMSF, pH 7.8). VLPs were precipitated with
40% ammonium sulfate and resuspended in 1× PBS (140 mM NaCl,
2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4), then puriﬁed via
iodixanol density gradient centrifugation. The VLP-containing 20%
iodixanol fraction was concentrated on a 300 kDa molecular weight
cut-oﬀ membrane (Sartorius) and quantiﬁed via immunoblot for
immunizations as described in (Kessans et al., 2016). A typical total
yield of a highly enriched VLP preparation in terms of its HIV-1 protein
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constituents was 275 mg/kg and 92 mg/kg for Gag and dgp41,
respectively.
2.9. Antibodies
The following antibodies were used for the indicated assays: anti-
p24 Gag polyclonal rabbit serum (Kessans et al., 2013); human anti-
MPER 2F5 (AIDS Reagent Program and the kind gift of Morgane
Bomsel); goat anti-human IgG-HRP (Sigma) for immunoblot; goat
anti-rabbit IgG-HRP (Santa Cruz) for immunoblot; rabbit anti-human
IgG-HRP (Santa Cruz) for ELISAs; rabbit anti-mouse IgG-HRP
(Calbiochem) for ELISAs; mouse IgA-kappa (ICL Labs) for ELISAs;
goat anti-mouse IgA (Sigma) for ELISAs.
2.10. Transmission electron microscopy (TEM)
BSC-40 cells grown in T75 ﬂasks were infected with each of the
vectors at an MOI=5 (for a total MOI=10) and harvested by trypsiniza-
tion 24 hpi. Cells were pelleted between all wash steps at 700×g for
5 min at 4 °C until embedded in agarose prior to secondary ﬁxation.
Pelleted cells were washed twice in 1× PBS (140 mM NaCl, 2 mM KCl,
10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). For primary ﬁxation, cells
were placed in 2% glutaraldehyde in PBS for 15 min at room
temperature followed by a second incubation with fresh ﬁxative for
1 h at 4 °C. Fixed cells were resuspended in 1% agarose and washed
three times in PBS for 30 min each at room temperature. Cells were
then ﬁxed with 1% osmium tetroxide in PBS for 1 h at room
temperature followed by four 15-min washes in water. A 0.2% uranyl
acetate solution in water was used to stain en bloc overnight at 4 °C
followed by three 15-min washes in water. An ethanol series from 20%
to 100% (anhydrous) was used for dehydration, increasing the ethanol
concentration by 20% every 10 min with three incubations in anhy-
drous ethanol. Spurr's resin was gradually introduced through 4- to 8-h
incubations with 1:3, 1:1, and 3:1 ratios of resin:100% ethanol
followed by three incubations in 100% resin. Cells were divided into
several blocks of Spurr's resin and polymerized at 60 °C for 36 h.
Sections were cut at 70 nm thick, and were placed on formvar-coated
copper slot grids followed by post-stain treatment with 2% uranyl
acetate and 3% Sato's lead citrate before imaging.
2.11. Mouse immunizations
All animal experiments were done with approval from the Arizona
State University Institutional Animal Care and Use Committee.
Six-week-old C57BL/6 mice (Jackson Laboratories) were split into
ﬁve groups. Three groups (n=5) received virus prime (VV) followed by
two boosts of either mock (Group 1), VLP (Group 2), or VV+VLP
(Group 3). Group 4 (n=3) received no virus prime and two VLP boosts
and Group 5 served as the naïve control (n=1). NYVAC-KC-Gag and
NYVAC-KC-dgp41 P2 stocks, each at a dose of 5×105 pfu, were mixed
together for a total dose of 1×106 pfu per mouse. Virus immunizations
prepared in Tris HCl pH 9.0 were injected intramuscularly (i.m.) into
the thigh. Plant-produced, gradient-puriﬁed VLPs were prepared in 1×
PBS pH 7.4 with 2 μg p24 and 1.2 μg MPER and mixed with Ribi
adjuvant (Sigma) per manufacturer's protocol to reach a ﬁnal concen-
tration of 2% oil [described previously in (Kessans et al., 2016)]. Mock
mice were injected i.m. with Tris HCl pH 9.0 buﬀer in equivalent
volumes. VACV and vehicle injections were delivered i.m. while VLPs
were delivered intraperitoneally (i.p).
Three immunizations were given to mice at days 0, 45, and 90.
Serum, fecal, and vaginal lavage samples were collected as previously
described (Kessans et al., 2016) every 2 weeks at days 0, 14, 28, 42, 56,
80, and at the endpoint of day 97 for analysis of Ab production. One
week post the ﬁnal boost (day 97), spleens were collected for analysis of
CD8 T-cell responses as described below.
Animals were monitored every 2–3 days for weight loss and other
signs of illness, as a measure of vector safety.
2.12. ELISA detection of IgG and IgA
Antibody production was measured via ELISA as previously
described (Kessans et al., 2016). Brieﬂy, serum, fecal, and vaginal
lavage samples were analyzed for IgG (serum) or IgA (mucosal sites)
speciﬁc for Gag p24 or gp41 MPER regions. Samples were analyzed in
threefold serial dilutions starting at 1:50, 1:2, and 1:5 for serum, fecal,
and vaginal lavage samples, respectively. Endpoint titers were calcu-
lated as the reciprocal of the dilution factor at which OD 490 nm was
equal to background levels (OD490 < 0.1) as previously described
(Matoba et al., 2008; Kessans et al., 2016). IgG1 and IgG2a isotypes
were detected with the same ELISA protocol, but with goat anti-mouse
IgG1-HRP or goat anti-mouse IgG2a-HRP secondary antibodies (Santa
Cruz Biotechnology) instead of total IgG. Puriﬁed mouse IgG1 kappa
chain or mouse IgG2a kappa chain primary antibodies (Sigma) were
used as controls.
For anti-VACV ELISAs, 96-well plates were coated with 107 pfu/
well of sucrose-cushion puriﬁed NYVAC-KC in 1× PBS, and the plates
were overnight at 37 °C. Wells were ﬁxed in 2% paraformaldehyde in
1× PBS for 10 min at 4 °C to inactivate the virus. Wells were washed
with buﬀer (150 mM NaCl, 0.5% Tween-20) then blocked with 5% non-
fat milk in 1× PBST. Plates were overlaid with serially diluted serum
samples and detected as previously described (Matoba et al., 2008;
Kessans et al., 2016).
2.13. Intracellular cytokine staining and ﬂow cytometry
Spleens were harvested in Hank's medium (Corning Cellgro) and
cells were strained through a 70 µm ﬁlter for resuspension in complete
RPMI [cRPMI: 10% FBS, penicillin (100 units/mL), streptomycin
(100 μg/mL), 2 mM L-glutamine]. Red blood cells were lysed with
ACK Lysing Buﬀer (Gibco) and splenocytes were resuspended in
cRPMI at a concentration of 2×107 cells/mL. Cells were plated at
1×106 cells/well and incubated for 5 h in the presence of Golgi Plug
(BD Biosciences) and 1 μg of one of ﬁve diﬀerent immunodominant
ZM96 Gag CD8 epitopes: LRSLYNTV (LRS8), VIPMFTAL (VIP8),
AMQMLKDT (AMQ8), YSPVSILDI (YSP9), EVKNWMTDTL (EVK10)
(synthesized by GenScript and resuspended according to manufac-
turer's protocol). Cells were stained with ﬂuorescently conjugated
antibodies: CD8-Paciﬁc Blue, TNFα-FITC, and IFNγ-PE (BD
Biosciences). Fixation and permeabilization was performed with a
Cytoﬁx/Cytoperm Kit (BD Biosciences) with ﬁnal resuspension in
FACS Buﬀer (1% FBS in 1× PBS). Samples were analyzed by ﬂow
cytometry on an LSR Fortessa. Data was analyzed using FlowJo Data
Analysis Software (FlowJo, LLC; Ashland, OR).
2.14. Statistics
All statistical analyses were performed in GraphPad Prism Software
(GraphPad Prism Software Inc.; La Jolla, CA). All data were analyzed
using a one-way ANOVA multiple comparison with Dunn's post-test.
Signiﬁcance cut-oﬀ was deﬁned as p < 0.05.
3. Results
3.1. Generation of recombinant Vaccinia virus vectors
NYVAC-KC-Gag and NYVAC-KC-dgp41 viruses were generated
through in vitro recombination (see Materials and Methods) (Fig. 1A
and B). Each gene was under control of a synthetic early/late VACV
promoter, ensuring the genes were expressed at all stages of viral
replication to maximize antigen production. Second round individual
plaques were screened for expression via immunoblot by probing for
either Gag or dgp41 expression. Immunoplaque assays for either Gag
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or dgp41 were performed to identify the plaque with highest purity for
further selection. This process was repeated until a plaque with > 98%
purity was identiﬁed and then used to grow a P2 stock. The ﬁnal
sucrose-pad puriﬁed P2 stock show Gag and dgp41 expression in BSC-
40 cell lysates at the proper size (Fig. 1C and D). It was noted during
selection that viruses recombining with dgp41 plasmids had reduced
plaque size and grew to much lower titers, suggesting that the HIV-1
gene makes the viral vector cytotoxic (data not shown).
Gag is known to be suﬃcient and necessary for HIV-1 VLP formation
and budding into the medium (Garoﬀ et al., 1998). To test whether BSC-
40-infected cells support VLP formation and budding, culture medium was
analyzed for the presence of Gag and dgp41. Indeed, Gag protein was
detected in culture medium of cells either infected with NYVAC-KC-Gag or
co-infected with NYVAC-KC-Gag and NYVAC-KC-dgp41 (Fig. 1E, Lanes 2
and 4). In contrast, dgp41 was detected only in the medium from co-
infected cells, not in medium from cells that were infected with NYVAC-KC-
dgp41 alone (Fig. 1E, Lane 4).
3.2. NYVAC-KC-Gag/dgp41 show cytotoxicity and in vitro VLP
production
These results indicate that export of dgp41 to the medium depends
on expression and export of Gag, suggesting that Gag VLPs and Gag/
dgp41 VLPs are released, respectively, from cells that express Gag
alone or co-express Gag and dgp41. We used TEM to test this
possibility. BSC-40 cells that were infected (MOI=5) with NYVAC-
KC, NYVAC-KC-Gag, NYVAC-KC-dgp41, or co-infected with Gag/dgp4,
were processed for TEM at 24 hpi.
In cells infected with the parental NYVAC-KC strain, viral replication
factories are clearly visible and all stages of viral replication are easily
identiﬁed (Fig. 2A). Mature virions (indicated by white arrows) are seen
both intracellularly (Fig. 2A-1) and extracellularly (Fig. 2A-2). Immature
virions with and without incorporated genomes are also abundantly visible
in this section (white and black triangles, respectively).
NYVAC-KC-Gag-, dgp41-, or co-infected cells have disorganized
viral factories and mature viral particles are rare (Fig. 2B-D). Many
early crescent formations are visible (black arrow), along with what
appears to be “unﬁlled” or empty virion shells (indicated by "E"). The
rarity of mature virus particles corresponds well to the smaller plaques
typical of these strains and their reduced titers, as noted above.
Instead, these infected cells appear to have large protein aggregates
or precipitates in their cytoplasm (“junk” indicated by "J"), mimicking
a phenotype associated with palmitate deﬁciency (Greseth and
Traktman, 2014). Additionally, NYVAC-KC-dgp41-infected cells de-
monstrate nuclear condensation (Fig. 2C-2, “nucleus” indicated by
"N"), a classic sign of apoptosis (Duprez et al., 2009). Furthermore, the
mitochondria (indicated by "M") in NYVAC-KC-Gag- and NYVAC-KC-
dgp41-infected cells appear to be malformed, potentially indicating
loss of structural integrity, which can also indicate occurrence of
apoptosis (Li and Dewson, 2015). This phenotype seems far more
drastic than that of NYVAC-KC-infected cells.
Importantly, in cells that were infected with NYVAC-KC-Gag
(Fig. 2B-2) or co-infected with NYVAC-KC-Gag and NYVAC-KC-
dgp41 (Fig. 2D-2), particles of approximately 100 nm in diameter
are seen budding at the cell surface (black stars). Similar structures
were not observed in any of the sections of cells expressing by itself
dgp41. Based on their size, and appearance, the particles are likely to
be HIV-1 Gag or Gag/dgp41 particles budding out of the cell. This
identiﬁcation is supported by our observation that Gag and dgp41
accumulated in the media of these infected cells (Fig. 1E).
3.3. Mouse immunizations
Six-week-old C57BL/6 mice were separated into ﬁve groups in
order to assess diﬀerent combinations of VACV and VLP immunization
regimens (Fig. 3A). Mice were given a total of three immunizations
separated by 45 days to allow for memory responses to develop prior to
boosting. Three groups (n=5) were primed with the combination of
NYVAC-KC-Gag and NYVAC-KC-dgp41 (denoted in all ﬁgures and text
as VV), followed by two boosts with either vehicle (Group 1), VLPs
alone (Group 2), or a combination of VV and VLPs (Group 3). A fourth
group (n=3) received a mock (vehicle) prime followed by boosts with
VLPs. The ﬁfth group served as a naïve control (n=1).
Monitoring of weight revealed that none of the mice in any group
lost weight (data not shown). This indicates little to no pathogenicity of
the virus and is consistent with previous virulence data for NYVAC-KC
(Kibler et al., 2011) and general safety of the plant-derived VLPs
(Kessans et al., 2016).
3.4. Serum IgG responses to Gag and MPER
Antigen-speciﬁc serum IgG responses were measured by ELISA
using p24 subunit or MPER peptide to detect Gag and dgp41 Ab
responses, respectively. Throughout, OD 450 nm values for the lowest
dilution tested (1:50) are shown both over time (Fig. 3B-C) and for
individual animals at the endpoint, Day 97 (Fig. 4A). Additionally,
endpoint titers were calculated for the ﬁnal serum samples and are
shown in Fig. 5A as the reciprocal of the dilution where the OD 450 nm
fell below background levels (OD< 0.1).
Fig. 1. Generation of recombinant Vaccinia viruses. Plasmids were cloned to
contain either full-length HIV-1 Gag (A) or deconstructed-gp41 (B) as pTM 815 and 816,
respectively. The genes are located between homologous recombination arms for the
VACV TK locus under the control of a synthetic early/late (E/L) promoter. Also included
is the neomycin resistance gene fused to GFP (GFP-neoR). (C and D) SDS-PAGE shows
full-length Gag (C) or dgp41 (D) expression in BSC-40's of NYVAC-KC-Gag (Lane 2) and
dgp41 (Lane 3) from the ﬁnal P2 virus stock used in animal experiments. Parental
NYVAC-KC shows no expression of either protein (Lane 1). (E) SDS-PAGE of ammonium
sulfate precipitations from media of BSC-40 cells infected with: NYVAC-KC (WT, Lane
1), Gag (Lane 2), dgp41 (Lane 3), or a co-infection of Gag/dgp41 viruses (G/d, Lane 4).
Samples were tested for both Gag (top) and dgp41 (bottom) expression.
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Serum IgG responses against both p24 and MPER antigens
remained undetectable in all groups until the ﬁrst sample (Day 55)
after the ﬁrst boost. Titers increased gradually and were boosted after
the ﬁnal immunization with VLPs (Fig. 3B-C), reaching signiﬁcant
levels at the endpoint analysis (Day 97) for both anti-p24 Gag and
anti-MPER responses (Fig. 4A). Endpoint Gag responses were highest
in the group boosted with a combination of VV and VLPs (VV/VV
+VLPs), while the group boosted with VLPs alone (VV/VLPs) also
showed signiﬁcant titers which were more variable responses among
animals (Fig. 5A). Anti-MPER serum IgG responses were lower than
Gag titers but showed a similar trend, reaching signiﬁcant levels in all
groups receiving VLPs regardless of prime/boost regimen (Fig. 4A).
However, the endpoint titer calculations showed no diﬀerence be-
tween groups, consistent with low Ab responses (Fig. 5A). It is
interesting to note that plant-produced VLPs appear to be largely
responsible for Ab stimulation because no detectable levels of anti-
bodies were present in the ﬁrst 45 days after a single dose of VV and
only reached detectable levels after the second immunization in those
groups that received VLPs.
3.5. Mucosal IgA responses to Gag and MPER
Gastrointestinal IgA responses to the dgp41 (MPER) antigen (as
determined by measuring the secreted Ab levels in fecal samples) were
Fig. 2. Electron microscopy of NYVAC-KC infected BSC-40s BSC-40 cells were infected at an MOI of 5 and harvested 24 hpi and prepared for transmission electron microscopy.
Cells were infected with either NYVAC-KC (A), NYVAC-KC-Gag (B), NYVAC-KC-dgp41 (C), or a co-infection with an MOI of 5 for each NYVAC-KC-Gag and NYVAC-KC-dgp41 (D). All
stages of VACV replication are present: mature virions (white arrow), immature virions (black triangle), immature virions with genome incorporated (white triangle), crescent formation
(black arrow), and ‘unﬁlled/empty’ virions (E). Budding HIV-1 Gag VLPs (black star) are also seen in those cells infected with NYVAC-KC-Gag. In certain infections, an accumulation of
cytoplasmic ‘junk’ (J) is visible. Other cellular features: mitochondria (M), nucleus (N). Scale bar: 500 nm for all images, except (B-2) and (D-2) images are 100 nm for HIV-1 VLPs.
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low but detectable (Fig. 4B), whereas anti-MPER IgA levels in vaginal
secretions were below our detection level irrespective of treatment
(Fig. 4C). Fecal anti-MPER IgAs were higher in groups that were
immunized using the prime/boost VV/VLPs regimen than groups that
were vaccinated with either VV or VLPs alone. Contrasting the two
groups, those mice that were boosted with a combination of VV and
VLPs exhibited marginally higher levels of fecal IgAs than those
boosted with VLPs alone, but their fecal IgA levels were signiﬁcantly
higher than the group that was primed with VV only. Interestingly,
levels of fecal and vaginal anti-p24 Gag IgAs were too low for detection
in all groups. This contrasts sharply with the generally much higher
titers of serum anti-p24 Gag IgGs as compared to serum anti-MPER
IgGs.
3.6. IgG isotyping
The two major IgG isotypes are IgG1 and IgG2a; the former is
consistent with stimulation of a Th2 response for B cell activation,
whereas the latter would be indicative of a Th1 response, which
primarily results in inﬂammatory cytokine production and killing of
intracellular pathogens (Snapper and Paul, 1987; Szabo et al., 2003).
Our results so far indicate that the most important immunogens
contributing to the elicitation of serum IgGs are the plant-derived
VLPs. To further substantiate this conclusion, we determined the Ab
isotypes contributing to this response, as protein-based vaccines (i.e.
immune-complexes) usually elicit IgG1 (Mosser and Edwards, 2008;
Martinez and Gordon, 2014).
To this end, serum samples from the endpoint for the two groups
which showed the highest serum IgG responses (VV/VLP and VV/VV
+VLP) were analyzed for their IgG isotype content by isotype-speciﬁc
ELISA (Fig. 5A and B, respectively). Both groups show high levels of
antigen-speciﬁc (either anti-p24 or anti-MPER) IgG1, but levels of
IgG2a were too low for detection, in agreement with our hypothesis.
3.7. Anti-vector antibody responses
Having substantiated the contribution of the Gag/dgp41 VLPs for
the elicitation of serum Ab responses against the two HIV-1 antigens,
the question arose whether or not the viral vector induced production
of anti-vector (i.e. anti-VV) serum Abs. Not surprisingly, mice belong-
ing to Group 3 that received a total of three doses of VV (prime plus two
boosts) showed signiﬁcant levels of anti-VV serum IgG at the endpoint
(Day 97, Fig. 6). However, a single dose of VV at Day 0 was not enough
to induce a potent anti-vector response (Group 1).
3.8. Gag-speciﬁc CD8 T cell responses
A major rationale to include Gag in an HIV-1 vaccine, especially a
live-vectored one, is its excellent ability to induce cellular responses. To
test induction of CD8 T cell responses, we tested the ability of peptides
corresponding to known Gag T-cell epitopes to stimulate proliferation
of CD8 T-cells among splenocytes obtained from vaccinated animals.
One week after the ﬁnal boost, splenocytes were harvested and
stimulated with ﬁve CD8 ZM96 Gag peptides that were previously
determined to be dominant in C57BL/6 mice (Chowell et al., 2015).
Peptides were assessed individually in order to obtain a better
resolution of their responses. CD8 T cells were analyzed for IFN-γ or
TNF-α production in response to peptide stimulation using cytokine
staining and ﬂow cytometry. Little to no TNF-α production was seen in
the ﬂow cytometry analysis (data not shown); however, IFN-γ produc-
tion was detectable in several groups. The group boosted with both VV
and VLPs showed signiﬁcant production of IFN-γ with two of the ﬁve
Gag peptides, AMQ8 and EVK10, at 2.6×105 CD8+ IFN-γ+ T cells
(3.5% of CD8+ T cells) and 1.91×105 CD8+ IFN-γ+ T cells (2.4%),
respectively (Fig. 7A and B). The other three peptides, LRS8, VIP8,
and YSP9 showed a similar trend as AMQ8 and EVK10 but with slightly
lower responses of CD8+ IFN-γ+ T cells at 1.73×105 (2.4%), 1.61×105
(2.1%), and 1.67×105 cells (2.3%), respectively, but failed to reach
signiﬁcance (Fig. 7C-E). When responses from all ﬁve peptides are
added together, the VV/VV+VLPs group has a total CD8 Gag-speciﬁc
mean response of 9.53×105 CD8+ IFN-γ+ T cells (12.7% of CD8 T
cells) (Fig. 7F). The total Gag-speciﬁc CD8 responses of the other
groups show minute diﬀerences between groups at 8.0% in Tris/VLP,
5.6% in VV/VLP, and 4.2% in VV/Tris. This suggests that plant-derived
Gag/dgp41 VLPs may be providing some component of the T cell
response and potentially boosting the initial VV-primed T cell re-
sponses as previously described for other Gag-containing VLPs
(Williamson and Rybicki, 2015). Future experiments plan to distin-
guish the roles in these responses.
4. Discussion
The RV144 Thai Trial demonstrated the strength of prime/boost
vaccination approach by eﬀectively combining two components that
were previously shown to be ineﬀective on their own: a live (albeit non-
replicating) canarypox viral vector (ALVAC) and a soluble protein boost
(AIDSVAX). The low eﬃcacy of the trial left much to be desired for
Fig. 3. Mouse immunization schedule. (A) Six-week-old C57BL/6 mice were
immunized at days 0, 45, and 90 with diﬀerent combinations of recombinant vaccinia
virus and plant-produced HIV-1 VLPs, represented as an image of a poxvirus or green-
enveloped particles, respectively. Vaccinia virus doses (VV) consisted of 1×106 pfu of
equally mixed NYVAC-KC-Gag and NYVAC-KC-dgp41 delivered i.m. while plant-
produced VLPs were mixed with Ribi adjuvant and delivered i.p. with 2 μg p24 and
1.2 μg MPER. Serum, fecal, and vaginal lavage samples were collected once every 2 weeks
(indicated by arrows). Serum samples were analyzed for antigen-speciﬁc IgG to p24 Gag
(B), or the MPER region of dgp41 (C), shown over the length of the experiment as the
ELISA OD 490 nm for the 1:50 dilution (lowest tested).
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widespread use as a vaccine while providing the conceptual basis for
further improvement (Rerks-Ngarm et al., 2009). The vaccine design
strategy presented here makes use of replicating, but highly attenuated,
vaccinia virus NYVAC-KC and plant-produced HIV Gag/dgp41 VLPs.
Our approach reﬂects two hypotheses. First, we suggest that in
addition to their excellent facility in eliciting T cell responses, replicat-
ing vectors are expected to increase antigen load, resulting in improved
immunogenicity. Second we propose that VLPs would improve pre-
sentation of relevant neutralizing determinants to the immune system.
Live recombinant vectors based on viruses belonging to a wide
range of families such as adenoviridae, poxviridae, and herpesviridae
have been previously tested for their immunogenicity (Rerks-Ngarm
et al., 2009; Hansen et al., 2013a; Huang et al., 2015; Buchbinder et al.,
2008; Tartaglia et al., 1992b). Considering the relative success of
ALVAC within the context of RV144, we and others have decided to
focus on poxviruses [see reviews (Gomez et al., 2012a; Pantaleo et al.,
2010; Jacobs et al., 2009)]. ALVAC is based on canarypox, which like
other avipoxviruses is naturally attenuated in humans due to its
restricted replication in non-avian cells (Taylor and Paoletti, 1988;
Taylor et al., 1988) accounting for ALVAC's high safety proﬁle (Team
AVEGP, 2001; Nitayaphan et al., 2004). Similarly, when developing
vaccinia-based vaccine vectors, eﬀorts were initially focused on strains
that are non-replicating in human cells (e.g. MVA and NYVAC), due to
safety concerns over potential complications with VACV infection in
immune-compromised individuals.
NYVAC was originally designed as a highly attenuated vaccine
Fig. 4. Systemic and mucosal antibody production. Endpoint (Day 97) samples were analyzed for serum IgG (A), and mucosal IgA in fecal (B) and vaginal lavage (C) samples.
Data is shown for both p24-speciﬁc (left) and MPER-speciﬁc (right) antibodies. Raw OD 490 nm values are shown for the lowest dilution factor tested (1:50). Statistically signiﬁcant
diﬀerences (p < 0.05) are indicated with an asterisk (*). Each marker represents a single animal.
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vector by speciﬁcally deleting 18 open reading frames from its parental
strain (Cop), thus preventing its replication in humans (Tartaglia et al.,
1992b). NYVAC has been tested as an HIV vaccine vector and was
shown to induce robust, polyfunctional CD4 and CD8 T cell responses
to Env and Gag-Pol-Nef (GPN) antigens in vaccinated individuals
(Harari et al., 2008, 2012). Because mucosal immune responses are
thought to be particularly important in protection against HIV-1, it was
signiﬁcant to note that such responses could be detected in the gut of
NYVAC-immunized patients (Perreau et al., 2011).
More recently, intensive research led to partial uncoupling of
attenuation and replication in NYVAC-based vectors showing enhanced
immunogenicity without compromising their safety. Speciﬁcally, re-
insertion of two host-range genes yielded NYVAC-KC. This strain is
capable of replicating in human cells and displays enhanced immune
activation, yet remains highly attenuated in a mouse model of
pathogenesis (Kibler et al., 2011; Quakkelaar et al., 2011), thus giving
this particular vector many desirable traits of a vaccine vector and was
chosen for use in the work presented here.
A large focus of HIV vaccine research is the HIV envelope protein
(Env/gp120) and variations thereof. However, gp120 is not highly
conserved and many critical neutralization targets are hidden or are
only exposed upon conformational change during viral entry, thus
limiting the eﬀectiveness of any NAb response to this antigen (Pancera
et al., 2014; Decker et al., 2005; Labrijn et al., 2003). Protein
Fig. 5. Endpoint serum IgG titers and isotyping. (A) Endpoint titers were calculated as the reciprocal of the dilution factor that had background level of OD 490 nm ( < 0.1).
Isotypes were determined by ELISA for antigen-speciﬁc IgG1 (B) or IgG2a (C) for both p24 (left) and MPER (right) serum IgG. OD 490 nm readings are shown and clearly indicate a
bias towards IgG1 production for both groups. Only endpoint (Day 97) serum samples were tested for these two groups because they had the highest responses. (*p < 0.05; **p < 0.01).
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engineering has attempted to resolve many of these issues, including
the design of SOSIP trimeric gp140 variants of Env to make a more
structurally accurate target necessary for eliciting speciﬁc types of
NAbs, including a design to speciﬁcally target nAb germline B cells
(Jardine et al., 2013; Billington et al., 2007; Du et al., 2009; Sellhorn
et al., 2012; Wan et al., 2009). Unfortunately, to date, no successful
clinical trials incorporating an engineered gp140 antigen have been
conducted. The HIV membrane protein gp41 contains the bnAb target
known as the MPER. This region requires the context of a membrane in
order to elicit the partially auto-reactive bnAbs found in HIV-infected
patients (Verkoczy et al., 2010, 2013; Haynes et al., 2005; Zhang et al.,
2016). In an eﬀort to achieve such responses in vaccination platforms,
VLPs oﬀer desirable qualities of enveloped, native virion structure for
displaying this important neutralization target.
VLPs are safe, yet immunogenic, components of several vaccines
and candidate vaccines for multiple infectious diseases [for a review see
(Kushnir et al., 2012)]. The potential for success of VLP-based vaccines
is indicated by the widespread use of the human papillomavirus (HPV)
vaccines Gardasil® (Merck and Co, 2006) and Cervarix®
(GlaxoSmithKline, 2014). To date, many plant-produced vaccines have
been tested in animal studies for immunogenicity for both human and
veterinary diseases (Rybicki, 2010; Scotti and Rybicki, 2013). Our
plant-produced HIV VLPs have the advantage of displaying the MPER
of gp41 in the native context of a Gag matrix, providing an immuno-
genic platform for humoral responses to both antigens (Kessans et al.,
2013, 2016). Additionally, HIV VLPs have been shown to boost T cell
responses following a heterologous prime (Chapman et al., 2013;
Chege et al., 2008; Pillay et al., 2010). CD8 T cell responses, often
targeting the Gag protein, are known to be associated with reduced
viral load, making this a key target for protective T cell immunity
(Kiepiela et al., 2007; Koup et al., 1994; Mudd et al., 2012; Stephenson
et al., 2012; Jiao et al., 2006).
Here we show that infecting susceptible cells with NYVAC-KC-Gag
with or without NYVAC-KC-dgp41 releases, respectively, ~100 nm Gag
or Gag/dgp41 VLPs into the extracellular medium (Fig. 1E). Such
particles can be seen by TEM budding out of the cell (Fig. 2B-2 and D-
2). Interestingly, dgp41 is detected in the medium only when co-
expressed with Gag (Fig. 1E), a result compatible with the notion the
two proteins assemble at the plasma membranes of cells in culture to
form VLPs. Although HIV-1 VLPs produced by other VACV-based
vectors were previously shown to elicit both humoral and cellular
immunity (Chen et al., 2005; Goepfert et al., 2011; Perdiguero et al.,
2015), in the experiments presented here, no antibodies were detect-
able in any group until after the ﬁrst plant-derived VLP immunization
(Fig. 3B-C). Among several potential explanations, the simplest one is
that production of Gag/dgp41 VLPs in vivo necessitates co-infection of
the same cell by the two viruses; this is achievable under cell culture
conditions where high MOI can be ensured, but is unlikely to occur in
an animal. We are currently pursuing VV vectors which co-express Gag
and dgp41 from the same locus to ensure in vivo Gag/dgp41 VLP
formation.
Another possible reason for the limited functionality of the dual
vectors is the poor replication and/or spread in mice, potentially due to
the cytotoxicity represented by protein precipitates in the cytoplasm
and nuclear condensation in NYVAC-KC-Gag-, dgp41- or co-infected
cells (Fig. 2B-D). The toxicity seen with TEM strongly correlates to
reduced plaque sizes and lower viral titers noted during viral selection
(data not shown). Gp41 is known to have a toxic cytoplasmic tail
(Postler and Desrosiers, 2013; Micoli et al., 2006), and it is possible
that this is responsible for the toxic eﬀects seen in Fig. 2. The
cytotoxicity of full-length gp160 has largely limited the use of gp41
in vaccine candidates despite the appealing, highly conserved target
region of the MPER. Additionally, this is consistent with published data
that NYVAC expressing HIV Gag-Pol-Nef induces extensive apoptosis
(Gomez et al., 2007). Currently, we are attempting to resolve this issue
by pursuing other VACV strains which are capable of limiting the toxic
eﬀects of the gp41 cytoplasmic tail in an eﬀort to make it easier to
produce vaccine candidates with full-length gp160 in its native,
structurally accurate conformation.
Despite the poor priming capacity of the VV in terms of eliciting Ab
responses against Gag and gp41, upon boosting with plant-derived
VLPs at Day 45, Ab production spiked with another increase after the
ﬁnal immunization at Day 97 (Fig. 3B-C). Endpoint anti-p24 Ab titers
reached signiﬁcant levels for serum IgG in the group boosted with just
VLPs (Group 2) or the combination of VV+VLPs (Group 3) (Fig. 5A),
and all groups boosted with any combination of VV and VLPs (Groups
2–4) reached signiﬁcance for MPER-speciﬁc serum IgG (Fig. 4A). As
noted above, due to the lack of detectable Abs prior to boosting with
VLPs, it seems that the plant-produced VLPs administered at a
relatively low dose, are largely responsible for boosting the Ab
responses following sub-responsive priming. In the groups with the
highest responses, these antibodies were shown to be entirely IgG1
with no detectable IgG2a (Fig. 5B-C). This agrees with our yet
unpublished data showing that plant-produced HIV VLPs stimulate a
predominant Th2 response through activation of M2b macrophages,
thus stimulating strong B cell Ab production.
Gag-speciﬁc CD8 T cell responses were highest in the group boosted
with VV+VLPs (Group 3), reaching 12.7% of CD8 T cells expressing
IFN-γ in response to the ﬁve Gag peptides (Fig. 7). While we do not
have a non-replicating vector in this study, these responses are higher
than MVA-induced Gag-speciﬁc CD8 T cells ( < 0.5%) in humans after
two doses (Keefer et al., 2011). Additionally, results here show higher
Gag-speciﬁc CD8 T cell responses than seen in mice after DNA-NYVAC
or DNA-MVA prime-boost regimen which elicit < 2% GPN/Env-
speciﬁc CD8 T cells ( < 0.5% Gag speciﬁc) and 12–15% GPN/Env-
speciﬁc CD8 T cells (5.5% Gag-speciﬁc), respectively (Gomez et al.,
2012b; Garcia-Arriaza et al., 2013). Taken together, this may suggest
that replication plays a role in increasing T cell responses. Results from
NYVAC HIV vaccines have shown proﬁciency for eliciting polyfunc-
tional T cell responses (i.e. antigen-speciﬁc T cells expressing multiple
cytokines) which are primarily eﬀector memory T cells (Harari et al.,
2008, 2012; Gomez et al., 2012b; Garcia-Arriaza et al., 2011). This is
important to explore in future experiments involving replicating
vectors such as NYVAC-KC due to the association of polyfunctional T
cells in the periphery with prevention of HIV infection (Betts et al.,
Fig. 6. Anti-VACV responses in serum at endpoint. Day 97 endpoint serum was
analyzed by ELISA for anti-vector responses with endpoint titers calculated as for Gag
and dgp41-speciﬁc serum IgG. The group which received a total of 3 doses of NYVAC-KC
vectors shows signiﬁcantly higher titers of VV-speciﬁc antibodies compared with any
other group (purple triangles). (***p < 0.001; ****p < 0.0001).
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2006). Additionally, it is important to note than when Env is included
in the MVA or NYVAC vector, T cell responses are skewed to be
primarily Env-speciﬁc with minimal Gag recognition (Harari et al.,
2008, 2012; Gomez et al., 2012b; Garcia-Arriaza et al., 2013; Garcia
et al., 2011; Mooij et al., 2009). Env-speciﬁc cytotoxic T lymphocyte
(CTL) responses were not protective in clinical trials nor correlated
with improved disease in natural infection (McMichael and Koﬀ, 2014),
while Gag-speciﬁc responses have been correlated with improved CD4
count and reduced viral load (Kiepiela et al., 2007; Koup et al., 1994;
Stephenson et al., 2012; Jiao et al., 2006; Ogg et al., 1998; Brander and
Fig. 7. Gag-speciﬁc CD8 T cell responses. One week after the ﬁnal immunization, peak CD8 T cell responses were measured by intracellular cytokine staining and ﬂow cytometry
for 5 immunodominant ZM96 Gag epitopes: AMQ8 (A), EVK10 (B), LRS8 (C), VIP8 (D), and YSP8 (E). Number of IFN-γ+ CD8+ T cells in the spleen is shown for each peptide
individually and the total response in the spleen (F) was calculated by adding the individual responses together for each group. The group boosted with VV and VLPs (purple) was
signiﬁcantly higher than the VV/Tris group (red) for two peptides and the overall response. (* p < 0.05; ** p < 0.01).
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Walker, 1999) and have epitopes which are less prone to CTL escape
(Goulder and Watkins, 2004).
Here we have shown that the combination of NYVAC-KC-Gag/
dgp41 replicating vaccinia virus vectors are immunogenic in mice and
elicit the best responses when administered together in a regimen
closely mimicking the RV144 clinical trial (VV/VV+VLPs). The
NYVAC-KC vector is a replicating, but safe, live viral vector with which
may induce higher Gag-speciﬁc CD8 T cell responses than with non-
replicating poxviral vaccine vectors, although a direct comparison
would be required to validate this point. Plant-produced VLPs show
proﬁciency for eliciting high Ab titers and may boost T cell responses
primed by the NYVAC-KC vectors, though this is the subject of future
studies. These vaccine candidates show promise as a cost-eﬀective,
scalable vaccine production platform to take forward in an eﬀort to
build upon the known success of the RV144 clinical trial to ﬁnd the
elusive HIV vaccine.
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